MyoKardia, Inc. News
Bristol-Myers Shares Gain After Positive Data From Opdivo Lung Cancer Trial
Bristol-Myers said its blockbuster drug, Opdivo, as well as chemotherapy helped patients suffering from resectable non-small cell lung cancer in a late-stage trial.
Morning Bell With Jim Cramer: Wait to Buy Regeneron
Jim Cramer shares stock market news about buying Regeneron stock, the Bristol Meyers deal, and Trump’s tweet about a stimulus package.
Stocks Close Higher; Trump Says He's Leaving Hospital Monday
Stocks end higher after President Trump tweets he's leaving Walter Reed Medical Center on Monday evening.
Is Bristol-Myers a Buy After $13.1 Billion Buy of MyoKardia?
MyoKardia is surging after a takeout deal from Bristol-Myers Squibb, which is marginally higher on the day. Does the deal make Bristol-Myers a buy?
Bristol-Myers Agrees To Buy Heart Treatment Maker MyoKardia for $13.1 Billion
MydoKardia's experimental heart treatment, Mavacamten, was granted a "breakthrough therapy designation' from the U.S. Food & Drug Administration in July of this year.
Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019
Moderna only went public in December, and is already creating a buzz.
We Want Bad News, Bears: Cramer's 'Mad Money' Recap
Jim Cramer says we actually want some bad news because definitive weaker news now drives stocks up and strong news takes them down.
Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap
Jim Cramer looks at the high-flying FANG stocks, and says he likes these companies best when their prices return to earth.
UnitedHealth Group Stock Edges Lower On Muted 2023 Profit Forecast
UnitedHealth, a Dow component, will host it annual investor event later today in New York.
Roku Stock Slides As KeyBanc Cuts Rating to 'Sector Weight' On Ad Weakness
Roku's eroding market share, and its need for new investment, will pressure near-term profits, according to KeyBanc analyst Justin Patterson.
Tesla Sentiment, Fundamentals Affected By Musk's Twitter Purchase - Morgan Stanley Survey
“Our investor survey reinforces our views that Elon Musk's recent involvement with Twitter has contributed to negative sentiment momentum in Tesla shares," said Morgan Stanley analyst Adam Jonas.
'Un-carrier' T-Mobile Makes a Very Verizon, AT&T 'Carrier' Move
Mobile carrier companies are always eager to increase revenue through fees customers pay and to outflank their competition with deals.